Kiadis Shareholders give irrevocable commitment to tender 36.6% of the shares under the offer by Sanofi
February 02, 2021 12:00 ET
|
Kiadis Pharma Netherlands B.V.
This is a joint press release by Sanofi ("Sanofi") and Kiadis Pharma N.V. ("Kiadis"), pursuant to the provisions of Sections 5 paragraphs 4 and 5 and Section 6 paragraph 2 of the Dutch Decree on...
Kiadis announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
January 22, 2021 01:00 ET
|
Kiadis Pharma N.V.
Amsterdam, The Netherlands, January 22, 2021 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative...
Kiadis draws €20 million from bridge loan with Sanofi
January 14, 2021 01:00 ET
|
Kiadis Pharma N.V.
This is a press release by Kiadis Pharma N.V. pursuant to Section 17 paragraph 1 of the European Market Abuse Regulation (596/2014) and in connection with the intended public offer by Sanofi for all...
Sanofi and Kiadis satisfy competition condition related to the tender offer
December 09, 2020 00:45 ET
|
Kiadis Pharma N.V.
This is a joint press release by Sanofi ("Sanofi") and Kiadis Pharma N.V. ("Kiadis"), pursuant to the provisions of Section 4, paragraph 3 of the Netherlands Decree in Public Takeover Bids (Besluit...
Kiadis issues “holdback” shares to former Cytosen shareholders
December 07, 2020 01:00 ET
|
Kiadis Pharma N.V.
This is a press release by Kiadis Pharma N.V. (Kiadis), pursuant to the provisions of Sections 5 paragraphs 4 and 5 and 6 paragraph 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare...
Kiadis announces new data at the 2020 ASH Annual Meeting and Exposition
December 06, 2020 07:10 ET
|
Kiadis Pharma N.V.
~Five presentations related to Kiadis’ K-NK cell therapy platform will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition~ An oral presentation (abstract...
Update on the intended offer by Sanofi for Kiadis
November 30, 2020 00:45 ET
|
Kiadis Pharma N.V.
This is a joint press release by Sanofi ("Sanofi") and Kiadis Pharma N.V. ("Kiadis"), pursuant to the provisions of Section 7, paragraph 1 sub a of the Netherlands Decree in Public Takeover Bids...
Kiadis to present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 24, 2020 01:00 ET
|
Kiadis Pharma N.V.
Amsterdam, The Netherlands, November 24, 2020 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative...
Kiadis issues options to newly hired employees to meet its existing obligations
November 20, 2020 01:00 ET
|
Kiadis Pharma N.V.
This is a press release by Kiadis Pharma N.V. (Kiadis), pursuant to the provisions of Sections 5 paragraphs 4 and 5 and 6 paragraph 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare...
Kiadis announces presentations at the 2020 ASH Annual Meeting and Exposition
November 13, 2020 01:00 ET
|
Kiadis Pharma N.V.
Amsterdam, The Netherlands, November 13, 2020 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative...